Abstract: Gel electrolytes include a mixture of red seaweed polysaccharide and metal hydroxide. The gel electrolytes are prepared by a method involving mixing, melting, and gelating the mixture of red seaweed polysaccharide and metal hydroxide. The gel electrolytes are suitable for use in metal-air batteries having metal-air electrochemical cells including an anode, a cathode, the gel electrolyte.

Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.

Abstract: The present invention relates to an orodispersible pharmaceutical solid dosage form comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof a pharmaceutically acceptable polymer suitable for forming a matrix with rasagiline or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, wherein rasagiline or a pharmaceutically acceptable salt thereof is trapped within the matrix, and wherein said dosage form exhibits a dissolution profile according to which (i) after 2 minutes at pH=7.0, less than 12% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and (ii) after 15 minutes at pH=1.2, more than 75% w/w of the rasagiline relative to the total rasagiline content of the dosage form is dissolved, and (iii) after 40 minutes at pH=1.

Abstract: This invention relates to Compound 1 (APX3330) salts and esters. The invention also provides compositions comprising a Compound 1 salt or ester. The invention also provides compounds of formula (I) and formula (II) and pharmaceutically acceptable salts thereof. The invention further provides compositions comprising a compound of formula (I) or formula (II), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or vehicle. The invention also provides methods for treating or preventing a disease, such as cancer, a liver disorder, an ocular disorder, a cardiovascular disorder, fibrosis, or an inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a Compound 1 salt or ester; or compound of formula (I) or formula (II), or pharmaceutically acceptable salt thereof.

Abstract: This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA e analytical applications, such as sequencing applications.

Abstract: A chemiresistive sensor has a low limit for detecting NO2 at ambient temperature. An active layer of the sensor includes a few-layer graphene material. The response of the sensor is not altered by relative humidity, and the sensor also demonstrates very low interference with ammonia, allowing this interference to be disregarded in the measurements.

Abstract: An access and mobility management function, AMF, entity receives an initial registration request from a communication device and transmits, responsive thereto, a network function, NF, discovery request to a network function repository function, NRF, entity, the NF discovery request including a communication device identifier and an NF type identifier. The NRF entity matches the communication device identifier with one of a plurality of communication device identifier ranges configured by the NRF entity, extracts a group identifier, groupId, configured for the one of the plurality of communication device identifier ranges, builds a list of registered NF profiles matching the NF type identifier and registered with the groupId, and transmits the list of registered NF profiles including the groupId and a NRF mapping indication to the AMF entity.

Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.

Abstract: There is provided compositions for the detection of target cellular material, the composition comprising: a chemically modified substrate; at least one binding moiety, wherein the binding moiety comprises a glycan; and at least one linker covalently linked to the substrate and the binding moiety by a first and second bond. There is also provided methods of preparation of such compositions and methods for detection of target cellular material, such as for detection of pathogenic microorganisms.

Abstract: The present application relates to the administration of plasma, fractions thereof, or mixtures thereof to humans or animals to treat or otherwise improve cognitive impairment disorders, including dementia (e.g., vascular dementia, dementia with Lewy bodies, dementia resulting from Alzheimer's disease, dementia resulting from Parkinson's disease, frontotemporal dementia, and dementia resulting from normal pressure hydrocephalus in humans, and cognitive dysfunction syndrome in companion animals), concussion, and traumatic brain injury.

Abstract: CDK7 inhibitors according to the formula (I): wherein X is —CH(OH)CH3, —CHFCH3, —CF2CH3, or —CF3; Y is —CH?CH2 or C2H?C2H2; and Z is CH(CH3)2 or C2H(CH3)(CH22H), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use are provided.

Abstract: The present invention relates to the field of genetic engineering, preferably the expression of recombinant proteins (RP). In particular, the invention relates to a promoter and variants thereof having an equal function and more than 90% sequence identity. The promoter comprises a fragment of 1147 base pairs (bp) of a first promoter, promoter of the ?-actin gene of the Cricetulus griseus genome, enriched in cytosine-guanine dinucleotides (RegCG). The first promoter can be upstream of a second promoter, cytomegalovirus (CMV) promoter. The invention also relates to vectors, transfected cellular lines and a method for producing RP in mammal cells that have been transfected with vectors containing said promoter or variants thereof.

Abstract: Procedure for the generation of a reflex tear secretion, which comprises the chemical stimulation of the cornea of the eye of a subject by applying a controlled jet of a gas with a high CO2 content, of at least 80% of CO2. Compact device (1,1?) for the generation of a reflex tear secretion, comprising a gas source (7) in the form of a disposable type cartridge containing a pressurized gas with a composition of at least 80% of CO2; and a pneumatic circuit connecting an outlet mouth of said gas source (7) with a gas outlet nozzle (3) of the device (1,1?), the circuit comprising pressure regulation means (8) and flow rate (17) regulation means suitable for ejecting puffs of gas through the outlet nozzle (3) at a predetermined pressure and flow rates.

Abstract: A bivalent, anti-MICA human monoclonal antibody formed by two or more heavy and light chains with a variable immunoglobulin domain neutralises the MICA protein in its soluble state and opsonises tumour cells expressing the antigen, stimulating adaptive immunity in the treatment of gastric cancer or other types of cancer in which the tumour cells express MICA in the soluble form or abundantly on their surface.

Abstract: A nose cleaning system for personal care and hygiene for the nose includes a nose cleaner having a cleaning head that has a textured surface; a neck that is wider than the cleaning head; a gripping body that is of smaller circumference (or perimeter) than the neck, and ergonomically designed to sit well in the fingers; a handle base; and a cover that is connectable to the neck; and a foaming nose cleanser having a pH of about 6. The foaming nose cleanser includes water (90%); a mix of synthetic detergents (6%); humectants or moisture enhancers (1.5%), salt (1.5%); and additives (1%).

Abstract: The industrial production of an extract by means of solid-liquid extraction improves the exchange of substances during extraction and allows enhanced dehumidification of a raffinate with residual moisture. The extraction is enhanced during a first dwell time by at least partially flooding a vessel in the form of at least one flow discharged with a secondary solvent or the obtained extract, swirling and keeping in suspension the primary mixture within the vessel by supplying the secondary solvent or the obtained extract via a foot area of the vessel, and/or moving the vessel relative to the extraction container within the obtained extract. The secondary solvent or the extract circulates in the extraction container by a circulation guide incorporating the extraction container from top to bottom relative to the extraction container, and the extract freed from raffinate with residual moisture obtained by dehumidification is supplied to the separated or to be separated extract.

Abstract: The present invention refers to an in vitro method for identifying patients at risk of suffering from colorectal cancer and/or colorectal adenomas, preferably advanced colorectal adenomas, based on measuring the expression profile or level of some miRNAs which are up-regulated or over-expressed in patients suffering from said diseases.

Abstract: Controlling the production of an extract using solid-liquid extraction that improves the exchange of material during the extraction process and allows a controlled dehumidification of a raffinate with residual moisture in order to obtain additional valuable extract is described. The steps include providing a first mass in an extraction container, supplying a second mass to the first mass without spatial constraints and distributing and mixing the second mass into and with the first mass, discharging a mixture of the extract and the raffinate from the extraction container, separating the discharged mixture into the raffinate with residual moisture and extracts released from the raffinate with residual moisture, and further treating the raffinate with residual moisture at least such that the residual moisture consisting of the extract is at least partly removed from the raffinate with residual moisture by dehumidification and is supplied to the already separated extract.

Abstract: The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.